Is the treatment duration for Venetoclax (Venetoclax) 28 days?

The treatment course of venetoclax is usually not fixed at 28 days, but 28 days are often used as a reference for a treatment cycle. In fact, the specific treatment duration will be individually adjusted based on the patient's condition, physical condition, drug response, and doctor's recommendations. Venetoclax, a small molecule targeted drug, has shown significant efficacy in the treatment of specific types of leukemia. Specifically, it achieves the purpose of treatment by inducing the apoptosis of cancer cells by blocking the expression of BCL-2 (BCL-2) protein.

For chronic lymphocytic leukemia (CLL), clinical trial results show that venetoclax combined with other drugs has an overall response rate (ORR) is as high as 90% or more, of which the complete remission rate (CR) is 30%-50%. This indicates that venetoclax has high efficacy in the treatment of CLL. In addition, its long-term efficacy is also very good, and the progression-free survival (PFS) can reach more than 5 years.

For patients with acute myeloid leukemia (AML), venetoclax has also achieved remarkable results in the treatment ofAML. In clinical trials, the overall response rate (ORR) of venetoclax combined with other drugs in the treatment of AML was 70%or above, of which the complete response rate (CR) is 40%-50%. These data fully demonstrate the effectiveness of venetoclax in the treatment of AML.

Finally, it needs to be emphasized that although venetoclax has significant efficacy, it may also cause some side effects such as low white blood cell count. Therefore, caution should be exercised during use and doctor's instructions should be followed to ensure the effectiveness and safety of the treatment.